Antitumor effect on immune control points (PD-1/PD-L1) in malignant neoplasms

Introduction. Immunotherapy of malignant neoplasms is a dynamically developing field. Diagnostic possibilities in determining the biomarkers tumor response to immunotherapy are discussed. The search for new diagnostic «points» being conducted on basis detailed studies carcinogenesis and cellular biological processes unchanged tissues. aim this work highlight one promising points influence tumors various localizations at present stage (the PD1/PD-L1 signaling pathway), taking into account available application practice Russian Federation. analysis published activity with immune checkpoint inhibitors was carried out. information research sources open systems E-Library, National Library Medicine (Pubmed), Cochrane last 10 years. article analyzes progress prospects localizations, including experience using PD-1 inhibitor pembrolizumab Chelyabinsk Regional Clinical Center Oncology Nuclear Medicine. Information use key prognosis evaluation therapy option highlighted. prognostic significance already implemented (PD-L1, MSI) discussed scientific press. Successful has been described treatment uterine body cancer, colon colorectal cancer. At same time, results study effectiveness uveal melanoma debatable. Conclusion. effect pathway (pembrolizumab, atezolizumab, etc.) directions ZNO localizations. determination number by immunohistochemical method, PCR (PD-L1 receptor, allows us identify those cases ZNO, which can give positive effect. New approaches sought pathways control through development combined drugs. And also continuing determine predictivity used immunotherapy.